Viking Therapeutics Inc (VKTX) concluded trading on Wednesday at a closing price of $25.79, with 4.18 million shares of worth about $107.87 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -60.81% during that period and on April 23, 2025 the price saw a gain of about 1.22%. Currently the company’s common shares owned by public are about 111.57M shares, out of which, 108.97M shares are available for trading.
Stock saw a price change of 11.60% in past 5 days and over the past one month there was a price change of -11.92%. Year-to-date (YTD), VKTX shares are showing a performance of -35.91% which decreased to -59.33% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $18.92 but also hit the highest price of $81.86 during that period. The average intraday trading volume for Viking Therapeutics Inc shares is 4.61 million. The stock is currently trading 8.13% above its 20-day simple moving average (SMA20), while that difference is down -4.80% for SMA50 and it goes to -45.51% lower than SMA200.
Viking Therapeutics Inc (NASDAQ: VKTX) currently have 111.57M outstanding shares and institutions hold larger chunk of about 73.35% of that.
The stock has a current market capitalization of $2.90B and its 3Y-monthly beta is at 0.75. It has posted earnings per share of -$1.01 in the same period. It has Quick Ratio of 33.09 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VKTX, volatility over the week remained 7.33% while standing at 9.19% over the month.
Stock’s fiscal year EPS is expected to drop by -60.63% while it is estimated to decrease by -34.89% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on April 08, 2025 offering a Neutral rating for the stock and assigned a target price of $30 to it. Coverage by Scotiabank stated Viking Therapeutics Inc (VKTX) stock as a Sector outperform in their note to investors on February 13, 2025, suggesting a price target of $102 for the stock. Stock get a Buy rating from B. Riley Securities on November 22, 2024.
